{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:28:41Z","timestamp":1794965321829,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Epidermolysis Bullosa Research Partnership"},{"name":"Dermatology Foundation Medical Career Development Award"},{"name":"Stanford MedScholars Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Epidermolysis bullosa simplex (EBS) comprises a group of rare, blistering genodermatoses. Prior work has been limited by small sample sizes, and much remains unexplored about the disease burden and health-related quality of life (QOL) of patients with EBS. The aim of this study was to characterize the most common patient-reported clinical manifestations and the health-related impact of QOL in EBS, and to examine differences in disease burden by age.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with a diagnosis of epidermolysis bullosa (EB) or their caregivers completed a one-time online survey administered by EBCare, an international online EB registry. Survey data from respondents self-reporting a diagnosis of EBS were analyzed for clinical and wound manifestations, medication use, and QOL (using Quality of Life in Epidermolysis Bullosa [QOLEB] scores). Differences across age groups were assessed using Kruskal\u2013Wallis and Fisher\u2019s exact tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 214 survey respondents with EBS. The mean age was 32.8\u00a0years (standard deviation\u2009=\u200919.2). Many respondents reported blisters (93%), recurrent wounds (89%), pain (74%), chronic wounds (59%), itch (55%), and difficulty walking (44%). Mean QOLEB score was 14.7 (standard deviation\u2009=\u20097.5) indicating a \u201cmoderate\u201d impact on QOL, and 12% of respondents required regular use of opiates. Findings were consistent in subgroup analyses restricted to respondents with diagnostic confirmation via genetic testing or skin biopsy (n\u2009=\u200963 of 214). Age-stratified analyses revealed differences in disease burden: younger respondents were more likely to self-report severe disease (24% vs. 19% vs. 5% for respondents aged 0\u20139 vs. 10\u201317 vs. 18\u2009+\u2009, p\u2009=\u20090.001), failure to thrive (9% vs. 15% vs. 3%, p\u2009=\u20090.02), and use of gastrostomy tubes (15% vs. 12% vs. 1%, p\u2009&lt;\u20090.001) and topical antibiotics (67% vs. 69% vs. 34%, p\u2009&lt;\u20090.001), while older respondents were more likely to be overweight or obese (6% vs. 0% vs. 51%, p\u2009&lt;\u20090.001) and have difficulty walking (24% vs. 46% vs. 48%, p\u2009=\u20090.04).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the largest international cross-sectional survey of EBS patients conducted, respondents reported extensive disease burden including significant wounding, pain, itch, difficulty walking, and impact on QOL. Age stratified disease manifestations. These findings suggest significant unmet need, and treatment and counseling for EBS patients should consider age-specific differences.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02433-3","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:08:01Z","timestamp":1657904881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex"],"prefix":"10.1186","volume":"17","author":[{"given":"Jodi Y.","family":"So","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivali","family":"Fulchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaron","family":"Nazaroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Gorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5510-6502","authenticated-orcid":false,"given":"Jean Y.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"2433_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18921","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.18921.","journal-title":"Br J Dermatol"},{"key":"2433_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-12","author":"JD Fine","year":"2010","unstructured":"Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010. https:\/\/doi.org\/10.1186\/1750-1172-5-12.","journal-title":"Orphanet J Rare Dis"},{"key":"2433_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/356244a0","author":"EB Lane","year":"1992","unstructured":"Lane EB, Rugg EL, Navsaria H, Leigh IM, Heagerty AHM, Ishida-Yamamoto A, Eady RAJ. A mutation in the conserved helix termination peptide of keratin 5 in hereditary skin blistering. Nature. 1992. https:\/\/doi.org\/10.1038\/356244a0.","journal-title":"Nature"},{"key":"2433_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0210-0","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, et al. Epidermolysis bullosa. Nat Rev Dis Prim. 2020. https:\/\/doi.org\/10.1038\/s41572-020-0210-0.","journal-title":"Nat Rev Dis Prim"},{"key":"2433_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.450","author":"PA Coulombe","year":"2012","unstructured":"Coulombe PA, Lee CH. Defining keratin protein function in skin epithelia: Epidermolysis bullosa simplex and its aftermath. J Invest Dermatol. 2012. https:\/\/doi.org\/10.1038\/jid.2011.450.","journal-title":"J Invest Dermatol"},{"key":"2433_CR6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01279-11.x","author":"E Pfendner","year":"2001","unstructured":"Pfendner E, Uitto J, Fine JD. Epidermolysis bullosa carrier frequencies in the US population [9]. J Invest Dermatol. 2001. https:\/\/doi.org\/10.1046\/j.1523-1747.2001.01279-11.x.","journal-title":"J Invest Dermatol"},{"key":"2433_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17012","author":"R Baardman","year":"2021","unstructured":"Baardman R, Yenamandra VK, Duipmans JC, Pasmooij AMG, Jonkman MF, van den Akker PC, Bolling MC. Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed? J Eur Acad Dermatol Venereol. 2021. https:\/\/doi.org\/10.1111\/jdv.17012.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2433_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23564.x","author":"E Pfendner","year":"2005","unstructured":"Pfendner E, Uitto J. Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. J Invest Dermatol. 2005. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.23564.x.","journal-title":"J Invest Dermatol"},{"key":"2433_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2020.05.001","author":"LM Mariath","year":"2020","unstructured":"Mariath LM, Santin JT, Schuler-Faccini L, Kiszewski AE. Inherited epidermolysis bullosa: update on the clinical and genetic aspects: Inherited epidermolysis bullosa. An Bras Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.abd.2020.05.001.","journal-title":"An Bras Dermatol"},{"key":"2433_CR10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03358.x","author":"HM Horn","year":"2000","unstructured":"Horn HM, Tidman MJ. The clinical spectrum of epidermolysis bullosa simplex. Br J Dermatol. 2000. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03358.x.","journal-title":"Br J Dermatol"},{"key":"2433_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17336","author":"A Reimer-Taschenbrecker","year":"2021","unstructured":"Reimer-Taschenbrecker A, Hess M, Hotz A, Fischer J, Bruckner-Tuderman L, Has C. Plantar involvement correlates with obesity, pain and impaired mobility in epidermolysis bullosa simplex: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2021. https:\/\/doi.org\/10.1111\/jdv.17336.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2433_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09306.x","author":"S Tabolli","year":"2009","unstructured":"Tabolli S, Sampogna F, Di Pietro C, Paradisi A, Uras C, Zotti P, Castiglia D, Zambruno G, Abeni D. Quality of life in patients with epidermolysis bullosa. Br J Dermatol. 2009. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09306.x.","journal-title":"Br J Dermatol"},{"key":"2433_CR13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.01121.x","author":"HM Horn","year":"2002","unstructured":"Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin Exp Dermatol. 2002. https:\/\/doi.org\/10.1046\/j.1365-2230.2002.01121.x.","journal-title":"Clin Exp Dermatol"},{"key":"2433_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0666-5","author":"J Brun","year":"2017","unstructured":"Brun J, Chiaverini C, Devos C, et al. Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex. Orphanet J Rare Dis. 2017. https:\/\/doi.org\/10.1186\/s13023-017-0666-5.","journal-title":"Orphanet J Rare Dis"},{"key":"2433_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4673","author":"JA Feinstein","year":"2019","unstructured":"Feinstein JA, Jambal P, Peoples K, et al. Assessment of the timing of milestone clinical events in patients with epidermolysis bullosa from North America. JAMA Dermatol. 2019. https:\/\/doi.org\/10.1001\/jamadermatol.2018.4673.","journal-title":"JAMA Dermatol"},{"key":"2433_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.903","author":"JD Fine","year":"2014","unstructured":"Fine JD, Bruckner-Tuderman L, Eady RAJ, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014. https:\/\/doi.org\/10.1016\/j.jaad.2014.01.903.","journal-title":"J Am Acad Dermatol"},{"key":"2433_CR17","first-page":"9","volume":"14","author":"DL Wong","year":"1988","unstructured":"Wong DL, Baker CM. Pain in children: comparison of assessment scales. Okla Nurse. 1988;14:9\u201317.","journal-title":"Okla Nurse"},{"key":"2433_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09347.x","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09347.x.","journal-title":"Br J Dermatol"},{"key":"2433_CR19","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1758","author":"WY Yuen","year":"2014","unstructured":"Yuen WY, Frew JW, Veerman K, van den Heuvel ER, Murrell DF, Jonkman MF. Health-related quality of life in epidermolysis bullosa: validation of the dutch QOLEB questionnaire and assessment in the dutch population. Acta Derm Venereol. 2014. https:\/\/doi.org\/10.2340\/00015555-1758.","journal-title":"Acta Derm Venereol"},{"key":"2433_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14802","author":"S Fulchand","year":"2021","unstructured":"Fulchand S, Harris N, Li S, Barriga M, Gorell E, De Souza M, Murrell D, Marinkovich MP, Krishna Yenamandra V, Tang JY. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: a global cross-sectional survey. Pediatr Dermatol. 2021. https:\/\/doi.org\/10.1111\/pde.14802.","journal-title":"Pediatr Dermatol"},{"key":"2433_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.028","author":"VA Eng","year":"2021","unstructured":"Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, de Souza MP, Murrell DF, Marinkovich MP, Tang JY. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: a global cross-sectional survey. J Am Acad Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.028.","journal-title":"J Am Acad Dermatol"},{"key":"2433_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01428.x","author":"JD Fine","year":"2004","unstructured":"Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol. 2004. https:\/\/doi.org\/10.1111\/j.1365-2230.2004.01428.x.","journal-title":"Clin Exp Dermatol"},{"key":"2433_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8223(95)00157-3","author":"K Birge","year":"1995","unstructured":"Birge K. Nutrition management of patients with epidermolysis bullosa. J Am Diet Assoc. 1995. https:\/\/doi.org\/10.1016\/S0002-8223(95)00157-3.","journal-title":"J Am Diet Assoc"},{"key":"2433_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31812f5667","author":"JD Fine","year":"2008","unstructured":"Fine JD, Johnson LB, Weiner M, Suchindran C. Gastrointestinal complications of inherited epidermolysis bullosa: cumulative experience of the national epidermolysis bullosa registry. J Pediatr Gastroenterol Nutr. 2008. https:\/\/doi.org\/10.1097\/MPG.0b013e31812f5667.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2433_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2009.10.022","author":"JT Wright","year":"2010","unstructured":"Wright JT. Oral manifestations in the epidermolysis bullosa spectrum. Dermatol Clin. 2010. https:\/\/doi.org\/10.1016\/j.det.2009.10.022.","journal-title":"Dermatol Clin"},{"key":"2433_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92759-9","author":"SPL Travis","year":"1992","unstructured":"Travis SPL, Turnbull AJ, Thompson RPH, McGrath JA, Schofield OM, Eady RAJ, Chan O, Fitzgerald O\u2019Connor A, Mayou B. Oral and gastrointestinal manifestations of epidermolysis bullosa. Lancet. 1992. https:\/\/doi.org\/10.1016\/0140-6736(92)92759-9.","journal-title":"Lancet"},{"key":"2433_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01612.x","author":"L Haynes","year":"2012","unstructured":"Haynes L, Mellerio JE, Martinez AE. Gastrostomy tube feeding in children with epidermolysis bullosa: consideration of key issues. Pediatr Dermatol. 2012. https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01612.x.","journal-title":"Pediatr Dermatol"},{"key":"2433_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1086-5","author":"K Martin","year":"2019","unstructured":"Martin K, Geuens S, Asche JK, et al. Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines. Orphanet J Rare Dis. 2019. https:\/\/doi.org\/10.1186\/s13023-019-1086-5.","journal-title":"Orphanet J Rare Dis"},{"key":"2433_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02495-5","author":"CCG Togo","year":"2020","unstructured":"Togo CCG, Zidorio APC, Gon\u00e7alves VSS, Hubbard L, de Carvalho KMB, Dutra ES. Quality of life in people with epidermolysis bullosa: a systematic review. Qual Life Res. 2020. https:\/\/doi.org\/10.1007\/s11136-020-02495-5.","journal-title":"Qual Life Res"},{"key":"2433_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12262","author":"EA Eismann","year":"2014","unstructured":"Eismann EA, Lucky AW, Cornwall R. Hand function and quality of life in children with epidermolysis bullosa. Pediatr Dermatol. 2014. https:\/\/doi.org\/10.1111\/pde.12262.","journal-title":"Pediatr Dermatol"},{"key":"2433_CR31","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0376","author":"C Van Scheppingen","year":"2008","unstructured":"Van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis CGB, Jonkman MF. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol. 2008. https:\/\/doi.org\/10.2340\/00015555-0376.","journal-title":"Acta Derm Venereol"},{"key":"2433_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/1359105310387954","author":"EF Williams","year":"2011","unstructured":"Williams EF, Gannon K, Soon K. The experiences of young people with epidermolysis bullosa simplex: a qualitative study. J Health Psychol. 2011. https:\/\/doi.org\/10.1177\/1359105310387954.","journal-title":"J Health Psychol"},{"key":"2433_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamadermatol.2021.1559","volume":"158","author":"JS Kirby","year":"2022","unstructured":"Kirby JS. Patient-reported outcomes in dermatology. JAMA Dermatol. 2022;158:97\u20138.","journal-title":"JAMA Dermatol"},{"key":"2433_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.33235\/wpr.29.2.86-97","volume":"6","author":"C Ireland","year":"2021","unstructured":"Ireland C, Pelentsov L, Kopecki Z. Caring for a child with Epidermolysis Bullosa: a scoping review on the family impacts and support needs. Wound Pract Res. 2021;6:66. https:\/\/doi.org\/10.33235\/wpr.29.2.86-97.","journal-title":"Wound Pract Res"},{"key":"2433_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.065","author":"GS Phillips","year":"2021","unstructured":"Phillips GS, Huang A, Augsburger BD, et al. A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa. J Am Acad Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jaad.2021.09.065.","journal-title":"J Am Acad Dermatol"},{"key":"2433_CR36","first-page":"66","volume":"6","author":"RJ Kuczmarski","year":"2002","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Wei R, Curtin LR, Roche AF, Johnson CL. 2000 CDC growth charts for the United States: Methods and development. National Center for Health Statistics. Vital Heal Stat. 2002;6:66.","journal-title":"Vital Heal Stat"},{"key":"2433_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.118","author":"DC Solis","year":"2021","unstructured":"Solis DC, Teng C, Gorell ES, Barriga M, Nazaroff J, Li S, Lu Y, Bruckner A, Marinkovich MP, Tang JY. Classification of 2 distinct wound types in recessive dystrophic epidermolysis bullosa: a retrospective and cohort natural history study. J Am Acad Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.118.","journal-title":"J Am Acad Dermatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02433-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:11:53Z","timestamp":1657905113000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02433-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2433"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02433-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was considered exempt from review by the Stanford University Institutional Review Board as the data do not contain any identifying information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data is sourced from the EBCare registry, which was created by Lotus Tissue Repair, Inc. (now Phoenix Tissue Repair, Inc.), DEBRA of America, and DEBRA International, and is currently managed by Invitae; these organizations were not involved in and did not influence the study design or outcomes of this research. Dr. de Souza is a shareholder in Phoenix Tissue Repair, Inc. and Phoenicis Therapeutics, Inc, and received a salary from Lotus Tissue Repair, Inc. Dr. Murrell is the creator of the Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire used in this study. Dr. Teng is a consultant to Abeona, Amryt and Castle Creek. Dr. Tang is a stockholder and consultant to BridgeBio and to PellePharm Inc. Drs. Tang, Teng, and Chiou are investigators for an EBS clinical trial sponsored by Biomendics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}